Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 44kWORD 10k
25 August 2021
Question for written answer  E-003956/2021
to the Commission
Rule 138
Ivan Vilibor Sinčić (NI), Mislav Kolakušić (NI)
 Answer in writing 
 Subject: The Commission’s signature of a potentially unbalanced contract with Pfizer under which Pfizer has extensive rights with extremely limited liability

Considering that MEPs have had very limited access to the Commission’s agreements on COVID-19 vaccines, and in the light of the draft agreement between Pfizer and the Albanian Government(1), we would like to know if the Commission’s agreement with Pfizer also includes the same:

1. acknowledgement that the efficacy of the vaccines is not currently known, that there may be adverse effects and that the vaccines will not be serialised?

2. waiver of all legal rights and remedies related to the violation of the agreed upon delivery schedule, including, in the case of a shortage, Pfizer solely adjusting the delivery schedule and diverting vaccines to other markets?

Considering Albania’s negotiated price of USD 12 per dose for 250 000 doses, what bulk discount has the EU negotiated?

Last updated: 7 September 2021Legal notice - Privacy policy